


RECEIVED

JUN 5 2001

TECH CENTER 1600/2900

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and documents submitted therewith are being deposited with the United States Postal Service as first class mail, postage prepaid thereon, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Tami Barnas
Tami Barnas

6/6/01
Date of Deposit

Applicant: Brooks, et al.)
Serial No.: 09/194,552) Group Art Unit: 1642
Filed: March 23, 1999) Examiner: A. Harris
For: METHODS AND COMPOSITIONS)
USEFUL FOR INHIBITION OF $\alpha\beta 5$) Our Ref.: TSRI 481.2
MEDIATED ANGIOGENESIS)

#15
KG
6-22-01

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In recognition of its continuing duty to disclose pursuant to 37 CFR §1.56, Applicant hereby submits the present Information Disclosure Statement in compliance therewith.

Pursuant to 37 CFR §1.98(d), enclosed herewith is a copy of 1) the Information Disclosure Statement and 2) the accompanying PTO Form 1449 filed in the application 08/514,799. Application 08/514,799, to which the present application is related as a continuation-in-part, was filed on August 14, 1995, and is now abandoned. Also, pursuant to 37 CFR §1.98(d), copies of the above references are not submitted herewith, as they are available in

06/12/2001 CCHRU1 00000003 09194552

03 FC:122

130.00 OP

06/12/2001 CCHRU1 00000003 09194552 180.00 OP
02 FC:126

the related patent application 08/514,799.

Applicants are also submitting additional references in the enclosed Information Disclosure Statement. Applicants understand that the interpretation given to each reference may differ from one individual to another. The PTO is therefore encouraged to independently examine the disclosed references. While the references provided in this Information Disclosure Statement may be material pursuant to 37 CFR §1.56, it shall not be construed to be an admission that the cited information is, or is considered to be, material to patentability unless specifically designated as such.

Applicants are filing the present statement pursuant to 37 CFR §1.97(c). The statement is accompanied by a check in the amount of \$180.00 as payment of the fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c)(2).

Also, in accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or, that if made, any search was complete or exhaustive, or that no other material information as defined in 37 CFR §1.56 exists.

Respectfully submitted,

June 6, 2001
Date

Emily Holmes
Emily Holmes, Reg. No. 40,652

THE SCRIPPS RESEARCH INSTITUTE
Office of Patent Counsel
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, CA 92037
(858) 784-2937